US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust NYSE Arca Biotechnology Index Fund

265.40

+5.212.00%

Post-market: 265.400.00000.00%16:10 EDT

Volume:187.28K

Turnover:49.67M

Market Cap:2.91B

PE:31.06

High:266.02

Open:260.84

Low:260.36

Close:260.19

52wk High:275.23

52wk Low:182.08

Shares:10.95M

Float Shares:10.95M

Volume Ratio:3.02

T/O Rate:1.71%

Dividend:- -

Dividend Rate:- -

EPS(TTM):8.55

EPS(LYR):37.75

ROE:19.96%

ROA:-0.16%

PB:1.04

PE(LYR):7.03

Loading ...

Overview Company News Filings

Alkermes Plc : Baird Raises Target Price to $61 from $58

THOMSON REUTERS

Alkermes Says ADHD Drug Candidate Showed Meaningful Improvements in Phase 1b Study; Shares Up Pre-Bell

MT Newswires Live

U.S. Stocks on the MOVE-Accenture, Arhaus, Alkermes

Alkermes jumps 8% to $46.99 after Phase I adult ADHD data

Alkermes Shares Rise 6.5% Premarket After Positive Results from Early-Stage Study of Adhd Drug

THOMSON REUTERS

Alkermes announces Phase 1b results of ALKS 7290 in ADHD

Alkermes Reports Positive Phase 1b Proof-of-Concept Data for ALKS 7290 in Adult ADHD

Bruker Wins over $6 Million UC Berkeley Order for High-Field NMR Systems

Bruker Receives Order for High-Field Nmr Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at Uc Berkeley

THOMSON REUTERS

Alkermes -Alks 7290 Generally Well Tolerated at All Doses in Healthy Volunteers and Adults with Adhd

THOMSON REUTERS

Alkermes Announces Positive Phase 1B Results Demonstrating Clinical Proof-of-Concept for Alks 7290 in Adults with Attention-Deficit Hyperactivity Disorder (Adhd)

THOMSON REUTERS

Alkermes - Phase 2 Study of Alks 7290 in Adults with Adhd Enrolling, Data Expected in 2027

THOMSON REUTERS

Corcept President, Oncology Roberto Wandenkolk Vieira Sells 296 Shares for $29,842.72

Alkermes Files Form 3 for Director Anne Clem Whitaker`

Analysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Xenon (XENE)

Corcept Says EU CHMP Backs Lifyorli Combo for Platinum-Resistant Ovarian Cancer

Corcept Therapeutics Incorporated - Ec to Issue Final Approval Decision in Q4 2026

THOMSON REUTERS

Corcept Announces Chmp Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

THOMSON REUTERS

FDA approves Ultragenyx gene therapy for Sanfilippo syndrome type A

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Twist Bioscience (TWST) and Medpace Holdings (MEDP)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/FBT/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"FBT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","market":"US","secType":"STK","nameCN":"First Trust NYSE Arca Biotechnology Index Fund","latestPrice":265.4,"timestamp":1791576000000,"preClose":260.19,"halted":0,"volume":187284,"hourTrading":{"tag":"盘后","latestPrice":265.4,"preClose":265.4,"latestTime":"16:10 EDT","volume":98478,"amount":26136057.26088,"timestamp":1791576604013,"change":0,"changeRate":0,"amplitude":0.010852},"delay":0,"changeRate":0.020023828740535685,"floatShares":10950002,"shares":10950002,"eps":8.545272,"marketStatus":"Post-Mkt","change":5.21,"latestTime":"10-09 16:19:40 EDT","open":260.84,"high":266.02,"low":260.36,"amount":49674080,"amplitude":0.021753,"askPrice":267.99,"askSize":200,"bidPrice":262.51,"bidSize":200,"shortable":3,"etf":1,"ttmEps":8.545272,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791590400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":260.19,"sharesOutstanding":11450002,"nav":263.61,"aum":2873349527.22,"bidAskSpread":0.000864,"preHourTrading":{"tag":"盘前","latestPrice":260.19,"preClose":260.19,"latestTime":"07:58 EDT","volume":3,"amount":780.5699999999999,"timestamp":1791547119615,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":265.4,"preClose":265.4,"latestTime":"16:10 EDT","volume":98478,"amount":26136057.26088,"timestamp":1791576604013,"change":0,"changeRate":0,"amplitude":0.010852},"volumeRatio":3.020661,"impliedVol":0.2454,"impliedVolPercentile":0.9044},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","floatShares":10950002,"roa":"-0.16%","roe":"19.96%","lyrEps":37.754725,"volumeRatio":3.020661,"shares":10950002,"dividePrice":0,"high":266.02,"amplitude":0.021753,"preClose":260.19,"low":260.36,"week52Low":182.08,"pbRate":"1.04","psRate":"701.07","week52High":275.23,"institutionHeld":0,"latestPrice":265.4,"eps":8.545272,"divideRate":0,"volume":187284,"delay":0,"ttmEps":8.545272,"open":260.84,"prevYearClose":206.52,"prevWeekClose":266.44,"prevMonthClose":272.26,"prevQuarterClose":272.26,"fiveDayClose":266.44,"twentyDayClose":261.85,"sixtyDayClose":249.28},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBT\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FBT","amount":1.1726,"announcedDate":"2024-12-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"First Trust NYSE Arca Biotechnology Index Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"},{"market":"US","date":"2022-01-10","symbol":"FBT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1641790800000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2021-12-30","symbol":"FBT","amount":2.2136,"defaultRemindTime":1640874600000,"name":"First Trust NYSE Arca Biotechnology Index Fund","recordDate":"2022-01-10","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBT\",market:\"US\",,,undefined,":[{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-10","value":2.2136,"currency":"USD"},{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":1.1726,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBT\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669166716","title":"Alkermes Plc : Baird Raises Target Price to $61 from $58","url":"https://stock-news.laohu8.com/highlight/detail?id=2669166716","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669166716?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:33","pubTimestamp":1789997614,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45D0EZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","MEDX","PSIL","ALKS","IBRN","BK4139","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669976165","title":"Alkermes Says ADHD Drug Candidate Showed Meaningful Improvements in Phase 1b Study; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2669976165","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669976165?lang=en_us&edition=fundamental","pubTime":"2026-09-21 20:43","pubTimestamp":1789994623,"startTime":"0","endTime":"0","summary":"Alkermes  said Monday its drug candidate ALKS 7290 showed clinically meaningful improvements from baseline on exploratory endpoints in a phase 1b study in patients with attention-deficit hyperactivity disorder or ADHD.The company said it measured improvements using the Adult ADHD Investigator Symptom Rating Scale and Clinical Global Impression-Severity Scale after 14 days of treatment.ALKS 7290 was generally well-tolerated at all doses tested in healthy volunteers and adults with ADHD, the company said. The study enrolled 50 adults with ADHD in a double-blind, placebo-controlled, parallel-group trial with two cohorts, it added.The company said it enrolled the first of an expected 312 participants in a phase-2 study this month. The trial will evaluate the safety and efficacy of once-daily and split doses of ALKS 7290 compared to placebo, with data expected next year.Shares of the company were up over 7% in Monday's premarket activity.Price: 46.50, Change: +3.11, Percent Change: +7.17","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MEDX","ALKS","PSIL","PSCH","IBRN","BK4139","FBT","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669099168","title":"U.S. Stocks on the MOVE-Accenture, Arhaus, Alkermes","url":"https://stock-news.laohu8.com/highlight/detail?id=2669099168","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669099168?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:52","pubTimestamp":1789991524,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Accenture, Arhaus, AlkermesSeptember 21 (Reuters)-Wall Street futures advanced on Monday, led by AI stocks, as a 2% slide in oil prices pulled Treasury yields lower on sig","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nL6N45D0I4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOOZ","CONI","ROBN","LU1430594728.SGD","BK4598","LU0265550359.USD","LU2247934214.USD","BULL","LU2211815571.USD","BK4168","SG9999018857.SGD","LU0323240290.USD","PSIL","MSTY.UK","LU0289739343.SGD","REXC","ICOI","LU1116320901.HKD","CRMX","LMI3.UK","LU0868494708.USD","MSTX","LU0149725797.USD","COIG","09799","IBRN","LU0868494617.USD","HOOC","LU0477156953.USD","LU0980610538.SGD","07399","LU0157215616.USD","LU0289960550.SGD","IAI","LU0738911758.USD","BK4178","09399","BK4596","BK4134","IE00BFSS8Q28.SGD","LU1861217088.USD","07311","MSTW","LU0323239441.USD","GRML","CRML","HK0000819398.USD","HOOD","IE0004445015.USD","LU1235294995.USD","WNTR","ALKS","MSTP","PSKY","3SMI.UK","LU1894683264.USD","BK4585","BK4588","LU1228905540.USD","07711","FINX","SG9999004303.SGD","SGXZ31699556.SGD","CRPT","LU1861559042.SGD","LU1861220207.SGD","HOII","ACN","BK4539","COIX","LU1894683348.USD","BKCH","LU0081259029.USD","COIO","CRMU","BPAY","BK4595","HOOY","ARHS","BK4023","LU1366333091.USD","LU1989772840.SGD","BK4600","HODU","BK4535","IE000M9KFDE8.USD","PSCH","BK4547","BLCK","LU0648001328.SGD","COYY","LU0511384066.AUD","LU0545562505.USD","LU0661504455.SGD","MEDX","LU1883839398.USD","LU0265550946.USD","IE00BJJMRX11.SGD","IE00BJJMRY28.SGD","BITQ","LU1201861249.SGD","BK4551","MSTZ","CONL","LU1003077747.HKD","BK4566","MSDD","MSTR","07799","LU0175139822.USD","LU2596442595.SGD","SMST","COIA","LU0342679015.USD","LU1046421795.USD","SG9999018865.SGD","IE00BFSS7M15.SGD","BK4125","LU0942090050.USD","LU0545039389.USD","LU0553294199.USD","MTYY","BK4554","HOYY","09711","BK4534","BK4108","MSTY","IE00BSNM7G36.USD","BK4213","MSII","SG9999014898.SGD","3LMI.UK","MSST","LU1989772923.USD","BULG","FDIG","CONY","CUE","HOOG","LU0130102774.USD","LU1228905037.USD","LU1116320737.USD","LU2360107671.USD","IE00B7KXQ091.USD","BULU","IMST","MSTC","SG9999014914.USD","HOOX","HOOW","09311","APED","LU1585245621.USD","FIAT","MSOO","SGXZ23171101.USD","DAPP","GLND","LU0289961442.SGD","MSTU","BK4533","COII","BK4581","MSTK","LU1506573853.SGD","SG9999014906.USD","HOOI","IE00BHPRN162.USD","LU2133065610.SGD","LU0130517989.USD","LU1823568750.SGD","SG9999014880.SGD","SMI3.UK","MST","BK4561","LU1032466523.USD","BK4516","BK4127","OWNB","BK4139","LU2381873111.SGD","IBLC","LU0949170772.SGD","COIN","WBD","COIW","BK4112","FBT","SG9999017495.SGD","CONX","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669163577","title":"Alkermes jumps 8% to $46.99 after Phase I adult ADHD data","url":"https://stock-news.laohu8.com/highlight/detail?id=2669163577","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669163577?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:50","pubTimestamp":1789991414,"startTime":"0","endTime":"0","summary":"07:46 EDT Alkermes (ALKS) jumps 8% to $46.99 after Phase I adult ADHD data Published first on TheFly – the ultimate source for real-time, market-mo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alkermes-jumps-8-to-46-99-after-phase-i-adult-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alkermes-jumps-8-to-46-99-after-phase-i-adult-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","ABVC","BK4139","PSIL","IBRN","ALKS","FBT","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150485","title":"Alkermes Shares Rise 6.5% Premarket After Positive Results from Early-Stage Study of Adhd Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150485?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:07","pubTimestamp":1789988867,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45A0RA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IBRN","PSCH","ALKS","FBT","PSIL","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669916887","title":"Alkermes announces Phase 1b results of ALKS 7290 in ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2669916887","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669916887?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:05","pubTimestamp":1789988737,"startTime":"0","endTime":"0","summary":"Alkermes (ALKS) announced topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alkermes-announces-phase-1b-results-of-alks-7290-in-adhd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alkermes-announces-phase-1b-results-of-alks-7290-in-adhd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BK4139","PSIL","ABVC","PSCH","IBRN","FBT","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669415062","title":"Alkermes Reports Positive Phase 1b Proof-of-Concept Data for ALKS 7290 in Adult ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2669415062","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669415062?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:01","pubTimestamp":1789988517,"startTime":"0","endTime":"0","summary":"Alkermes reports positive Phase 1b proof-of-concept data for ALKS 7290 in adult ADHDAlkermes reported positive Phase 1b topline results for ALKS 7290 in adults with ADHD; results have already been pre","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDL2WW99h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","MEDX","PSIL","PSCH","ALKS","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150625","title":"Bruker Wins over $6 Million UC Berkeley Order for High-Field NMR Systems","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150625","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150625?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:01","pubTimestamp":1789988463,"startTime":"0","endTime":"0","summary":"Bruker wins over $6 million UC Berkeley order for high-field NMR systemsBruker received a multi-system order from the University of California, Berkeley for high-field NMR instrumentation at the Pines","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDLb5g2fh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","LU0757428866.USD","LU1815336091.USD","FBT","TINY","BRKR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150544","title":"Bruker Receives Order for High-Field Nmr Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at Uc Berkeley","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150544","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150544?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:00","pubTimestamp":1789988401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA4FDCZM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1815336091.USD","FBT","BRKR","TINY","BK4121","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669505181","title":"Alkermes -Alks 7290 Generally Well Tolerated at All Doses in Healthy Volunteers and Adults with Adhd","url":"https://stock-news.laohu8.com/highlight/detail?id=2669505181","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669505181?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:00","pubTimestamp":1789988400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA9RZ6JR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","ALKS","IBRN","FBT","PSCH","MEDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150548","title":"Alkermes Announces Positive Phase 1B Results Demonstrating Clinical Proof-of-Concept for Alks 7290 in Adults with Attention-Deficit Hyperactivity Disorder (Adhd)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150548?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:00","pubTimestamp":1789988400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA9RZ6JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","PSIL","ALKS","BK4139","FBT","IBRN","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150512","title":"Alkermes - Phase 2 Study of Alks 7290 in Adults with Adhd Enrolling, Data Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150512?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:00","pubTimestamp":1789988400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA9RZ6JR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALKS","PSIL","MEDX","BK4139","IBRN","FBT","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668358979","title":"Corcept President, Oncology Roberto Wandenkolk Vieira Sells 296 Shares for $29,842.72","url":"https://stock-news.laohu8.com/highlight/detail?id=2668358979","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668358979?lang=en_us&edition=fundamental","pubTime":"2026-09-19 07:54","pubTimestamp":1789775650,"startTime":"0","endTime":"0","summary":"Corcept President, Oncology Roberto Wandenkolk Vieira sells 296 shares for $29,842.72Corcept’s President, Oncology Roberto Wandenkolk Vieira sold 296 common shares on Sep. 16, 2026 at $100.82.He repor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL5zJb0H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept President, Oncology Roberto Wandenkolk Vieira Sells 296 Shares for $29,842.72","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","PSCH","BK4532","LU1559883803.SGD","BK4007","CORT","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668789973","title":"Alkermes Files Form 3 for Director Anne Clem Whitaker`","url":"https://stock-news.laohu8.com/highlight/detail?id=2668789973","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668789973?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:48","pubTimestamp":1789764537,"startTime":"0","endTime":"0","summary":"Alkermes files Form 3 for director Anne Clem Whitaker`Alkermes director Anne Clem Whitaker filed a Form 3 initial statement of beneficial ownership dated Sept. 14, 2026.Disclaimer:This news brief was ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL7wyxYN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","FBT","MEDX","BK4139","PSCH","PSIL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668273689","title":"Analysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668273689","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668273689?lang=en_us&edition=fundamental","pubTime":"2026-09-19 00:30","pubTimestamp":1789749010,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Corcept Therapeutics (CORT) and Xenon (XENE) with bu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-corcept-therapeutics-cort-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-corcept-therapeutics-cort-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SBIO","HCSG","IBRN","XENE","LU1559883803.SGD","BK4532","LABU","PSCH","XBI","BK4581","CORT","XLV","BK4585","BK4139","BK4007","BK4588","LU0128526141.USD","FBT","BK4137","LU0566484027.USD","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668923679","title":"Corcept Says EU CHMP Backs Lifyorli Combo for Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2668923679","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668923679?lang=en_us&edition=fundamental","pubTime":"2026-09-18 20:01","pubTimestamp":1789732903,"startTime":"0","endTime":"0","summary":"Corcept says EU CHMP backs Lifyorli combo for platinum-resistant ovarian cancerEU drug regulator’s CHMP backed marketing authorization for Corcept’s Lifyorli (relacorilant) with nab-paclitaxel in plat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDLcd4Vr8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","BK4007","BK4532","LU1559883803.SGD","PSCH","CORT","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668923688","title":"Corcept Therapeutics Incorporated - Ec to Issue Final Approval Decision in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2668923688","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668923688?lang=en_us&edition=fundamental","pubTime":"2026-09-18 20:00","pubTimestamp":1789732800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nTUA4Q98SD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0566484027.USD","LU1559883803.SGD","BK4532","CORT","BK4007","FBT","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668923684","title":"Corcept Announces Chmp Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668923684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668923684?lang=en_us&edition=fundamental","pubTime":"2026-09-18 20:00","pubTimestamp":1789732800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nTUA4Q98SD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0566484027.USD","BK4532","CORT","BK4007","FBT","PSCH","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668991067","title":"FDA approves Ultragenyx gene therapy for Sanfilippo syndrome type A","url":"https://stock-news.laohu8.com/highlight/detail?id=2668991067","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668991067?lang=en_us&edition=fundamental","pubTime":"2026-09-18 02:35","pubTimestamp":1789670130,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration approved Fayuvi, which it calls “the first treatment for pediatric patients with mucopolysaccharidosis type I...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-approves-ultragenyx-gene-therapy-for-sanfilippo-syndrome-type-a-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-approves-ultragenyx-gene-therapy-for-sanfilippo-syndrome-type-a-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","CNCR","SYNB","GNOM","IBB","TBXU","FBT","BK4585","BK4588","LABU","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668996274","title":"Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Twist Bioscience (TWST) and Medpace Holdings (MEDP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668996274","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668996274?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:30","pubTimestamp":1789648219,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKS), Twist Bioscience (TWST) and Medpa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-twist-bioscience-twst-and-medpace-holdings-medp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-twist-bioscience-twst-and-medpace-holdings-medp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBT","IDNA","MEDP","LU2065170008.USD","PSCH","IBRN","LU0029874061.USD","BK4585","XBI","PSIL","BK4581","LU2065171311.SGD","ALKS","MEDX","BK4137","XLV","WDNA","BK4121","LABU","LU2065171402.SGD","LU0128526141.USD","BK4588","GNOM","TWST","ARKG","LU2065169927.USD","HCSG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}